You are here

  • Home
  • Archive
  • Volume 80, Issue 2
  • Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Article info

Article menu
Download PDFPDF
Letter
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Authors

  • Arielle Mendel Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada PubMed articlesGoogle scholar articles
  • Sasha Bernatsky Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada PubMed articlesGoogle scholar articles
  • Anca Askanase Division of Rheumatology, Columbia University Irving Medical Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Sang-Cheol Bae Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seongdong-gu, Republic of Korea PubMed articlesGoogle scholar articles
  • Ann Elaine Clarke Division of Rheumatology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada PubMed articlesGoogle scholar articles
  • Nathalie Costedoat-Chalumeau Centre de Référence Maladies Auto-immunes et Systémiques Rares, Service de Médecine Interne, Hôpital Cochin, Paris, France PubMed articlesGoogle scholar articles
  • Dafna D Gladman Lupus Program, Centre for Prognosis Studies in the Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Caroline Gordon Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK PubMed articlesGoogle scholar articles
  • John Hanly Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada PubMed articlesGoogle scholar articles
  • Søren Jacobsen Copenhagen Lupus and Vasculitis Clinic, Section 4242, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Ken Kalunian Division of Rheumatology, University of California San Diego School of Medicine, La Jolla, California, USA PubMed articlesGoogle scholar articles
  • Anselm Mak Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore PubMed articlesGoogle scholar articles
  • Marta Mosca Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy PubMed articlesGoogle scholar articles
  • Bernardo A Pons-Estel Regional Center for Autoimmune and Rheumatic Diseases of Rosario, Sanatorio Parque, Rosario, Argentina PubMed articlesGoogle scholar articles
  • Guillermo Ruiz-Irastorza Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain PubMed articlesGoogle scholar articles
  • Murray Urowitz Lupus Program, Centre for Prognosis Studies in the Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Évelyne Vinet Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Arielle Mendel, Rheumatology, McGill University Health Centre, Montreal, QC H3G1A4, Canada; arielle.mendel{at}mail.mcgill.ca
View Full Text

Citation

Mendel A, Bernatsky S, Askanase A, et al
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics
Annals of the Rheumatic Diseases 2021;80:1-2.

Publication history

  • Received May 30, 2020
  • Revised June 15, 2020
  • Accepted June 16, 2020
  • First published June 25, 2020.
Online issue publication 
January 12, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage